Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Renal Cell 10Urinary Bladder Neoplasms 7Prostatic Neoplasms 6Breast Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Carcinoma, Transitional Cell 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Recurrence 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Hematologic Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Urologic Neoplasms 1Thrombocytosis 1Stroke 1Stomach Neoplasms 1Soft Tissue Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Disulfides × Genitourinary × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡